慢性掻痒症市場は2020年から2034年の間に年平均成長率8.6%で成長すると予測される｜DelveInsight

The chronic pruritus treatment landscape is poised for significant expansion across the seven major markets (7MM), fueled by the emergence of breakthrough therapies including Dupilumab, Linerixibat, and Volixibat, among others. Growth is further supported by a rising patient burden — driven by an aging global population, greater exposure to environmental triggers, increasing incidence of chronic inflammatory and autoimmune diseases, and improved recognition of the condition among clinicians.

DelveInsight's latest Chronic Pruritus Market Insights report offers a detailed examination of existing treatment approaches, drugs currently in development, individual therapy market shares, and market size estimates spanning 2020 to 2034. The analysis covers the United States, the EU4 nations (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Highlights from the Report

• The total chronic pruritus market across the 7MM was valued at USD 3.5 billion in 2024.
• Dupilumab is projected to generate approximately USD 700 million across the 7MM by 2034.
• In 2024, roughly 98 million total prevalent cases of chronic pruritus were recorded across the 7MM, with around 22 million of those being diagnosed cases.
• Major pharmaceutical players advancing pipeline therapies include Sanofi, Regeneron, GlaxoSmithKline, Galderma, Chugai Pharmaceutical, Mirum Pharmaceuticals, and several others.
• Notable pipeline candidates include DUPIXENT (dupilumab), Linerixibat (GSK2330672), NEMLUVIO/MITCHGA (nemolizumab), and Volixibat.
• In November 2024, GSK announced encouraging results from the global Phase III GLISTEN trial evaluating Linerixibat in adult patients with cholestatic pruritus associated with primary biliary cholangitis (PBC), presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. Regulatory submissions are anticipated in the U.S. in 2025, and in Europe and Japan in 2026.
• Also in November 2024, Mirum Pharmaceuticals disclosed interim data from the Phase IIb VINTAGE study of Volixibat for PBC-related cholestatic pruritus at the same AASLD conference.
• In September 2024, the Phase III LIBERTY-CPUO-CHIC trial assessing DUPIXENT for adults with severe, uncontrolled chronic pruritus of unknown origin did not achieve statistical significance on its primary itch-response endpoint, although numerical trends were favorable. All secondary itch-related endpoints showed nominally significant improvements. The broader Phase III program also includes a second pivotal study currently in planning.

Discover which therapies are expected to grab the major chronic pruritus market share @ Chronic Pruritus Market Report

Understanding Chronic Pruritus

Chronic pruritus is characterized by persistent itching lasting more than six weeks and can profoundly diminish a patient's quality of life. It is associated with a wide range of dermatological and systemic conditions. The condition involves intricate interactions between the immune and nervous systems, with cytokines and neuropeptides playing central roles in sustaining the itch response. This biological complexity makes accurate diagnosis difficult, requiring thorough skin assessments to differentiate between primary dermatological disorders and secondary skin changes. Because the causes vary widely, effective treatment must be personalized and address the underlying etiology.

A structured diagnostic approach is essential given the broad spectrum of potential causes. Evaluation typically begins with a comprehensive medical history and physical examination to identify any skin abnormalities or indicators of systemic disease. Standard laboratory tests are conducted to assess liver, kidney, and thyroid function, alongside checks for iron deficiency and elevated inflammatory markers. In some cases, additional investigations — such as skin scrapings or biopsies — may be needed to rule out infections or malignancy.

Epidemiology Overview

The epidemiology section of the report provides an in-depth look at historical, current, and projected patient populations across the 7MM. Key segmentation categories include:

• Total prevalent cases of chronic pruritus
• Total diagnosed prevalent cases
• Gender-specific diagnosed cases
• Age-specific diagnosed cases
• Severity-specific diagnosed cases
• Etiology-specific diagnosed cases

Current Treatment Landscape

Managing chronic itch requires a targeted and individualized strategy based on its specific cause and underlying biological mechanisms. Effective care depends on identifying whether the itch originates from a skin disease, a systemic illness, a neurological disorder, or a psychological condition — and then applying appropriate therapies accordingly. As scientific knowledge advances, the treatment paradigm is shifting from broad symptom management toward precision-based medicine, with newer agents specifically designed to interrupt the pathways responsible for itch.

When itching is secondary to skin conditions such as atopic dermatitis or psoriasis, topical corticosteroids remain the first-line anti-inflammatory treatment. They suppress immune activity to reduce redness, swelling, and discomfort. For patients who cannot tolerate steroids, or in anatomically sensitive areas, calcineurin inhibitors provide a steroid-free option by blocking T-cell activation and curbing inflammation.

In moderate to severe atopic dermatitis, systemic treatment with dupilumab — a monoclonal antibody targeting the IL-4 and IL-13 signaling pathways — has demonstrated meaningful symptom relief and improved skin barrier integrity by addressing Type 2 inflammatory activity.

For patients with chronic kidney disease-associated pruritus (CKD-aP), difelikefalin — a selective kappa-opioid receptor agonist administered intravenously — offers targeted relief by acting on peripheral sensory neurons and immune cells. Its limited penetration into the central nervous system reduces the risk of opioid-related central side effects.

Currently, the approved therapy landscape for chronic pruritus remains narrow, with only three marketed options:

• KORSUVA/KAPRUVIA (kappa opioid receptor agonist)
• LIVMARLI (IBAT inhibitor)
• BYLVAY/KAYFANDA (IBAT inhibitor)

To know more about chronic pruritus treatment guidelines, visit @ Chronic Pruritus Management 

Pipeline Therapies and Developing Companies

Discover more about chronic pruritus drugs in development @ Chronic Pruritus Clinical Trials

Market Dynamics

The chronic pruritus market is expected to undergo meaningful transformation in the coming years. Collaborative care involving dermatologists, neurologists, allergists, and mental health professionals is enhancing diagnostic precision and enabling more personalized treatment strategies. The growing use of peripheral kappa-opioid receptor (KOR) agonists — which target itch with fewer central nervous system side effects — represents a notable advancement in tolerability and patient experience.

The relatively limited commercial focus on chronic pruritus compared to broader itch-related conditions also highlights an unmet opportunity for specialized therapeutic innovation. Greater attention to quality-of-life outcomes is encouraging the development of care models that holistically address both psychological burden and physical symptoms.

Several emerging therapies are under active investigation, and the introduction of these treatments is expected to significantly reshape the market over the forecast period. Improved diagnostic rates and better treatment access are anticipated to drive further market growth across the 7MM.

However, a number of challenges could restrain market expansion:

• Chronic pruritus of unknown origin remains difficult to treat due to a lack of validated biomarkers, inadequate targeting of neural sensitization, and over-reliance on conventional treatments such as antihistamines and corticosteroids.
• The diverse underlying causes — including various systemic diseases — complicate precise diagnosis and delay the adoption of newer therapies.
• High treatment costs, reimbursement barriers, and limited access to specialist care pose additional constraints.
• Underdiagnosis, underreporting, and low public awareness of the condition continue to hinder market development.
• Pipeline setbacks and therapy discontinuations remain ongoing risks.

Report Metrics at a Glance

Report Scope

• Assessment of currently marketed and emerging chronic pruritus therapies
• Key market forecast assumptions and market outlook
• Competitive intelligence including SWOT analysis and market entry strategies
• Unmet needs, key opinion leader perspectives, and analyst commentary
• Market access and reimbursement analysis by country

Download the report to understand which factors are driving chronic pruritus market trends @ Chronic Pruritus Market Trends

Table of Contents

Key Insights

Report Introduction

Chronic Pruritus Market Overview at a Glance

Executive Summary

Key Events

Disease Background and Overview

Methodology

Epidemiology and Patient Population

Patient Journey

Marketed Drugs

Emerging Drugs

Chronic Pruritus – 7MM Market Analysis

KOL Views

Unmet Needs

SWOT Analysis

Market Access and Reimbursement

Appendix

DelveInsight Capabilities

Disclaimer

About DelveInsight

Related Reports

Psoriasis Market (2034) — Covers disease background, epidemiology, market trends, and key companies including AnaptysBio, Takeda, Bristol-Myers Squibb, Amgen, Novartis, and others.

Psoriasis Pipeline (2025) — Profiles clinical and pre-clinical pipeline drugs with insights into companies such as Mylan, Biocad, Janssen Pharmaceuticals, Arcutis Biotherapeutics, GlaxoSmithKline, and more.

Atopic Dermatitis Market (2034) — Provides epidemiological data, market forecasts, and competitive analysis with coverage of companies including Sanofi, Pfizer, Eli Lilly, LEO Pharma, UCB Pharma, and others.

Atopic Dermatitis Pipeline (2025) — Comprehensive pipeline overview featuring companies such as AstraZeneca, Kyowa Kirin, Novartis, Bristol-Myers Squibb, Connect Biopharma, and many more.

About DelveInsight

DelveInsight is a premier business consulting and market research firm dedicated exclusively to the life sciences sector. The company assists pharmaceutical organizations by delivering comprehensive, end-to-end solutions designed to enhance their performance. Seamless access to all healthcare and pharma market research reports is available through DelveInsight's subscription-based platform, PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kanishk Kumar

Email: kkumar@delveinsight.com 

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/